BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2020 9:59:40 AM | Browse: 433 | Download: 541
 |
Received |
|
2020-07-17 15:12 |
|
Peer-Review Started |
|
2020-07-17 15:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-08-22 23:26 |
|
Revised |
|
2020-08-28 14:51 |
|
Second Decision |
|
2020-09-15 12:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-09-15 23:53 |
|
Articles in Press |
|
2020-09-15 23:53 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-21 06:58 |
|
Publish the Manuscript Online |
|
2020-10-26 09:59 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Che Hseuh Yang, Kuo Tung Chen, Yi Sheng Lin, Chao Yu Hsu, Yen Chuan Ou and Min Che Tung |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yi Sheng Lin, MD, Attending Doctor, Surgeon, Surgical Oncologist, Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, No. 699 Sec. 8, Taiwan Blvd., Wuqi Dist., Taichung City 435403, Taiwan. tung12197@gmail.com |
| Key Words |
Molecular targeted therapy/methods; Receptors; Vascular endothelial growth factor/drug effects; Vascular endothelial growth factor/therapeutic use; Vascular endothelial growth factor A/drug effects; Nephrotic syndrome/drug therapy |
| Core Tip |
Trials of anti-vascular endothelial growth factor (VEGF) therapy mostly focused on drugs with more potent to its receptors and with better progression-free survival, but few reports discussed about nephrotoxicity induced by anti-VEGF drugs, especially achieving improvement by regimens’ adaptions. This study is the second published case report about the successful adaption from lenvatinib, a more potent tyrosine kinase inhibitor (TKI), to sorafenib, a less potent TKI, to improve the nephrotoxicity and, meanwhile, achieve the therapeutic goal of cancer control. |
| Publish Date |
2020-10-26 09:59 |
| Citation |
Yang CH, Chen KT, Lin YS, Hsu CY, Ou YC, Tung MC. Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report. World J Clin Cases 2020; 8(20): 4883-4894 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i20/4883.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i20.4883 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
